Zai Lab Limited
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG00HFX3N90
ZLAB
Zai Lab Limited
GICS: -
·
Sector: Healthcare
·
Sub-Sector: Biotechnology
NAME
Zai Lab Limited
ISIN
US98887Q1040
TICKER
ZLAB
MIC
XNAS
REUTERS
ZLAB.OQ
BLOOMBERG
ZLAB US
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Mon, 14.04.2025
Zai Lab
US98887Q1040
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its first quarter 2025 financial results and provide recent corporate updates on May 8, 2025, before the opening of the U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (8:00 p.m. HKT).
Conference Call and Webcast ...
Zai Lab
Wed, 26.03.2025
Zai Lab
US98887Q1040
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from preclinical studies of the Company’s internally discovered and developed next-generation, investigational oncology therapies, ZL-6201, an LRRC15 antibody-drug conjugate (ADC) for the treatment of sarcoma, and ZL-1222, a PD-1 targeted IL-12 immunocytokine for cancer immunothe...
Zai Lab
Thu, 13.03.2025
Zai Lab
US98887Q1040
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after systemic therapy.
“In China...
Zai Lab
Mon, 03.03.2025
Zai Lab
US98887Q1040
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that members of the Company’s senior management team will participate in the following investor conferences in March 2025:
Leerink Partners 2025 Global Healthcare Conference
Fireside Chat: Monday, March 10, 2025, 9:20 a.m. EST
Location: Miami, FL
Jefferies Biotech on the Beach Summit
T...
Zai Lab
Thu, 27.02.2025
Zai Lab
US98887Q1040
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the fourth quarter and full-year 2024, along with recent product highlights and corporate updates.
“2024 was a defining year for Zai Lab, marked by strong sales growth, financial strength, and significant pipeline progress. As we look ahead, 2025 is set to be a tran...
Zai Lab
Tue, 28.01.2025
Zai Lab
US98887Q1040
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its fourth quarter and full year 2024 financial results and provide recent corporate updates on February 27, 2025, before the opening of the U.S. equity markets. The announcement will be followed by a conference call and webcast at 8:00 a.m. ET (9:00 p.m. HKT).
Confer...
Zai Lab
Thu, 23.01.2025
Zai Lab
US98887Q1040
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ZL-1310, a potential highly active first-in-class DLL3 antibody-drug conjugate (ADC), for the treatment of small cell lung cancer (SCLC).
“Receiving an Orphan Drug Designation for ZL-1310 recognizes ...
Zai Lab
Fri, 17.01.2025
Zai Lab
US98887Q1040
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the treatment of schizophrenia in adults.
“There are more than 8 million patients living with schizophrenia in China who face significant unmet needs due to the limited ...
Zai Lab
Wed, 15.01.2025
Zai Lab
US98887Q1040
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the China subpopulation of the global Phase 3 innovaTV 301 study, demonstrating a clinically meaningful improvement in overall survival with TIVDAK treatment for patients with previously treated recurrent or metastatic cervical cancer compared to chemotherapy....
Zai Lab
Fri, 10.01.2025
Zai Lab
US98887Q1040
Zai Lab Limited (Nasdaq: ZLAB; HKEX: 9688) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced an exclusive collaboration and license agreement for the development and commercialization of Vertex’s povetacicept (pove) in mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore (the licensed territory). Pove is a rec...
Zai Lab
Information on product placements
SMART * AD
P R O D U C T S U G G E S T I O N S
